Thinking about how to solve the dilemma of setting medical insurance payment standards caused by multiple indications?

When the medical insurance department sets the payment standard for the drugs in the reimbursement catalog, drugs with multiple different indications often cause confusion

How to formulate the medical insurance payment standard:

Judging from international experience, some countries use differential pricing for different indications, while others use uniform pricing, and there is no certain rule

The reason why the pricing of multi-indication drugs can cause trouble is the following thinking path: the pricing of a new drug in a certain indication should consider the therapeutic effect of the drug for this indication, and its effect is better than other drugs in the indication The extent of this, and the price of other drugs

The reason why the pricing of multi-indication drugs is troublesome is because of the following thinking path:

The above thoughts are essentially pricing new drugs based on medical value

The above thoughts are essentially pricing new drugs based on medical value

Must we stick to the method of value pricing?

The value currently discussed is essentially a comparison of the utility of investing scarce resources here and elsewhere

The value currently discussed is essentially a comparison of the utility of investing scarce resources here and elsewhere

However, this is not the only standard for pricing, nor should it be the only standard for medical insurance to formulate payment standards

As a buyer, the payment standard established by medical insurance must be higher than the cost of the supplier, and there must be a certain profit margin, otherwise the supplier will not need to continue to supply, and can invest resources elsewhere to make profits

From the perspective of cost, regardless of the number of indications for the drug, the cost can be uniformly calculated for reasonable pricing